Home / Fact sheets / Netherlands / Cervical qualitative data
Check also the following factsheets: Netherlands, Breast, Colorectal
Country fact sheet: Netherlands
CERVICAL CANCER SCREENING PROGRAMME
Reporting year for qualitative data: | 2016 |
Source of qualitative data: | Other (EU Report 2017) |
Organization of screening | |
An individual/team/institution responsible to coordinate the programme: | Yes |
Dedicated budget for screening programme: | Yes |
Documented cancer screening policy: | Yes |
Nature of documentation of the policy: | Law |
Year programme was initiated: | 1970 |
Programme introduction was preceded by a pilot: | - |
Screening tests provided free of charge: | Yes |
Diagnostic tests provided free of charge: | Yes |
Treatment services provided free of charge: | - |
Information system and data collection | |
System that collects data: | Individual |
• Identification of eligible population: | - |
• Screening participation: | - |
• Screening test results: | - |
• Further assessment: | - |
• Final pathology diagnosis: | - |
• Cancer staging: | - |
• Treatment: | - |
The information system exists at national or sub-national level: | Individual: Unknown Aggregated: Unknown |
The information system collects data outside the programme (opportunistic screening/private sector): | - |
Cancer screening data is linked with population-based cancer registry (PBCR): | Yes |
Screening protocol | |
A screening protocol or guideline: | - |
Year of published/updated protocol: | - |
Target age (min-max) and screening interval [months] for each test: | Cytology (30-64 years / [60 months]) |
Triaging test used: | None |
Self-collection HPV recommended: | - |
"Screen and treat" included in the protocol: | - |
Treatment modality for "screen and treat": | - |
Invitations for screening and further assessment | |
Initiatives to create population awareness by the Health Ministry/Health Authority: | - |
Invitations to eligible population: | Yes |
Source of the eligible individuals identified: | |
Method of invitation: | Letter |
Screening kit included with the invitation: | No |
Screen positive individuals actively contacted for further assessment: | No |
Individuals with a precancer or cancer diagnosis actively contacted: | - |
Quality Assurance (QA) of screening activities | |
Documented standard operating procedure/policy for QA: | Yes |
An individual/team/institution responsible for QA: | Yes |
Accreditation of lab services: | - |
Accreditation of pathology services: | - |
Documented performance indicators: | Yes |
Reference standards for performance indicators: | - |
Evaluation reports published in the last five years: | Yes |
Performance indicators | |
Reporting year for quantitative data: | 2016 |
Source of quantitative data: | Report (EU Report 2017) |
Age range and regional limitation if applicable: | 30-59 years |
Invitation coverage (%): | 96.7 |
Participation rate (%): | 66.0 |
Examination coverage (%): | |
Completeness of data related to screening test results (%): | 100 |
Completeness of data related to further assessment results (%): | 76.1 |
Further assessment (Colposcopy referral) rate (%): | 1.7 (all ages) |
Further assessment participation rate (%): | 76.1 (all ages) |
Detection rate for CIN2+ (x 1000): | 7.58 (all ages) |
Detection rate for CIN3+ (x 1000): | 4.64 (all ages) |
Detection rate for invasive cancer (x 1000): | |
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000): | 59.5 (all ages) |
Positive Predictive Value for CIN3+ (x 1000): | 36.5 (all ages) |
Positive Predictive Value for invasive cancer (x 1000): | |
More quantitative data (2009/Cytology) |
Check also the following factsheets: Netherlands, Breast, Colorectal